Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 102

1.

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.

Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N.

Cancers (Basel). 2019 Jul 31;11(8). pii: E1084. doi: 10.3390/cancers11081084.

2.

Radiofrequency ablation for hepatocellular carcinoma: Clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability.

Minami Y, Minami T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M.

Hepatol Res. 2019 Jul 13. doi: 10.1111/hepr.13407. [Epub ahead of print]

PMID:
31301213
3.

Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.

Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Hiraoka A, Johnson P, Kudo M.

Cancers (Basel). 2019 Jul 7;11(7). pii: E952. doi: 10.3390/cancers11070952.

4.

Response Evaluation Criteria in Cancer of the Liver versionĀ 5 (RECICL 2019 revised version).

Kudo M, Ikeda M, Ueshima K, Sakamoto M, Shiina S, Tateishi R, Hasegawa K, Furuse J, Miyayama S, Murakami T, Yamashita T, Kokudo N.

Hepatol Res. 2019 Jun 24. doi: 10.1111/hepr.13394. [Epub ahead of print]

PMID:
31231916
5.

Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.

Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Komeda Y, Kudo M.

J Med Virol. 2019 Oct;91(10):1804-1810. doi: 10.1002/jmv.25515. Epub 2019 Jul 2.

PMID:
31199513
6.

Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.

Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7.

PMID:
29631810
7.

Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B.

Hagiwara S, Nishida N, Watanabe T, Ida H, Sakurai T, Ueshima K, Takita M, Komeda Y, Nishijima N, Osaki Y, Kudo M.

Antivir Ther. 2018;23(6):513-521. doi: 10.3851/IMP3225.

PMID:
29438098
8.

Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.

Ogawa C, Morita M, Omura A, Noda T, Kubo A, Matsunaka T, Tamaki H, Shibatoge M, Tsutsui A, Senoh T, Nagano T, Takaguchi K, Tani J, Morishita A, Yoneyama H, Masaki T, Moriya A, Ando M, Deguchi A, Kokudo Y, Minami Y, Ueshima K, Sakurai T, Nishida N, Kudo M.

Oncology. 2017;93 Suppl 1:113-119. doi: 10.1159/000481241. Epub 2017 Dec 20.

9.

Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma.

Minami Y, Minami T, Hagiwara S, Ida H, Ueshima K, Nishida N, Murakami T, Kudo M.

Eur Radiol. 2018 May;28(5):1986-1993. doi: 10.1007/s00330-017-5162-8. Epub 2017 Dec 1.

PMID:
29196855
10.

Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.

Ueshima K, Nishida N, Kudo M.

Dig Dis. 2017;35(6):611-617. doi: 10.1159/000480257. Epub 2017 Oct 17.

PMID:
29040994
11.

Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.

Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M.

Dig Dis. 2017;35(6):589-597. doi: 10.1159/000480208. Epub 2017 Oct 17.

PMID:
29040992
12.

Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.

Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M.

Dig Dis. 2017;35(6):583-588. doi: 10.1159/000480186. Epub 2017 Oct 17.

PMID:
29040991
13.

Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.

Ida H, Hagiwara S, Kono M, Minami T, Chishina H, Arizumi T, Takita M, Yada N, Minami Y, Ueshima K, Nishida N, Kudo M.

Dig Dis. 2017;35(6):565-573. doi: 10.1159/000480183. Epub 2017 Oct 17.

PMID:
29040989
14.

Unique Characteristics Associated with Sustained Liver Damage in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals.

Kono M, Nishida N, Hagiwara S, Minami T, Chishina H, Arizumi T, Minaga K, Kamata K, Komeda Y, Sakurai T, Takenaka M, Takita M, Yada N, Ida H, Minami Y, Ueshima K, Watanabe T, Kudo M.

Dig Dis. 2017;35(6):556-564. doi: 10.1159/000480148. Epub 2017 Oct 17.

PMID:
29040988
15.

Hepatocarcinogenesis Is Associated with Serum Albumin Levels after Sustained Virological Responses with Interferon-Based Therapy in Patients with Hepatitis C.

Umehara Y, Hagiwara S, Nishida N, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Chishina H, Ueshima K, Komeda Y, Arizumi T, Watanabe T, Kudo M.

Dig Dis. 2017;35(6):548-555. doi: 10.1159/000480147. Epub 2017 Oct 17.

PMID:
29040987
16.

Evidence and topics of chemotherapy for hepatocellular carcinoma.

Ueshima K, Kudo M.

Nihon Shokakibyo Gakkai Zasshi. 2017;114(9):1621-1628. doi: 10.11405/nisshoshi.114.1621. Japanese. No abstract available.

PMID:
28883291
17.

The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization.

Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M.

Liver Cancer. 2017 Jun;6(3):227-235. doi: 10.1159/000475777. Epub 2017 May 9.

18.

Influence of Liver Inflammation on Liver Stiffness Measurement in Patients with Autoimmune Hepatitis Evaluation by Combinational Elastography.

Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M.

Oncology. 2017;92 Suppl 1:10-15. doi: 10.1159/000451011. Epub 2017 Jan 6.

19.

Malignant Transformation of Hepatocellular Adenoma.

Kwok WY, Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Iwanishi M, Chishina H, Kono M, Ueshima K, Komeda Y, Arizumi T, Enoki E, Nakai T, Kumabe T, Nakashima O, Kondo F, Kudo M.

Oncology. 2017;92 Suppl 1:16-28. doi: 10.1159/000451012. Epub 2016 Dec 17.

20.

Contrast-Enhanced Tissue Harmonic Imaging versus Phase Inversion Harmonic Sonographic Imaging for the Delineation of Hepatocellular Carcinomas.

Kono M, Minami Y, Iwanishi M, Minami T, Chishina H, Arizumi T, Komeda Y, Sakurai T, Takita M, Yada N, Ida H, Hagiwara S, Ueshima K, Nishida N, Kudo M.

Oncology. 2017;92 Suppl 1:29-34. doi: 10.1159/000451014. Epub 2016 Dec 15.

Supplemental Content

Loading ...
Support Center